130,601 research outputs found

    Evolution and revolution at the menopause

    No full text
    David W. Sturdee and Alastair H. MacLenna

    Primum non nocere

    No full text
    David Sturdee and Alastair MacLenna

    Prevention of osteoporosis is still a valid aim for hormone therapy

    No full text
    David W. Sturdee and Alastair H. MacLenna

    Not all placebos are equally pleasing

    No full text
    David W. Sturdee, Alastair H. MacLenna

    Is combined estrogen/progestogen hormone therapy worth the risk?

    No full text
    David W. Sturdee and Alastair H. MacLenna

    The pendulum swings back; estrogen is now beneficial if started at the right time

    No full text
    David W. Sturdee and Alastair H. MacLenna

    Reducing the problems of the progestogen

    No full text
    David W. Sturdee and Alastair H. MacLenna

    How low can you go?

    No full text
    David W. Sturdee and Alastair H. MacLenna

    Should epidemiology, the media and quangos determine clinical practice?

    No full text
    David Sturdee and Alastair MacLenna

    IMS Updated recommendations on postmenopausal hormone therapy

    No full text
    copyright 2007 International Menopause Society Issued on behalf of the Board of the International Menopause Society by; Amos Pines (President); David W. Sturdee (General Secretary); Martin H. Birkhuser (Treasurer); Hermann P. G. Schneider; Marco Gambacciani; Nick Pana
    corecore